| Date | Title | Description | Source |
| 29.03.2024 | A new Ozempic rival helps patients lose fat, but keep their ... | Health A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a wei... | businessin... |
| 30.11.2023 | Altimmune Announces Positive Topline Results from MOMENTUM 4... | Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss contin... | einpresswi... |
| 20.12.2022 | Altimmune Announces Positive Topline Results from 24-Week (1... | Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at ... | einpresswi... |
| 28.09.2021 | French biotech and Pfizer find positives in data for Ly... | French biotech Valneva and partner Pfizer continued to reveal positive results from its Ph... | endpts.com... |
| 15.03.2021 | AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vacci... | New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis Un... | globenewsw... |
| 12.03.2021 | Altimmune Expands AdCOVID™ Manufacturing Collaboration with ... | GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq... | globenewsw... |
| 08.03.2021 | Altimmune to Present at Upcoming Conferences | GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stag... | globenewsw... |
| 25.02.2021 | Altimmune Commences Enrollment in Phase 1 Clinical Trial of ... | Nasal spray may offer room temperature distribution that could reduce logistical challenges for heal... | globenewsw... |
| 25.02.2021 | Altimmune Announces Financial Results for the Year Ended Dec... | Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced
Development of AdCOVID Vectors Targe... | globenewsw... |
| 22.07.2020 | Altimmune Announces Manufacturing Agreement with Vigene Bios... | GAITHERSBURG, Md., July 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage... | signetheal... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi ... | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the ... | endpts.com... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as... | endpts.com... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Figh... | Alain Mérieux, founder of BioMérieux.AFP via Getty Images | forbes.com... |
| 21.08.2019 | Altimmune Announces $3.7M In Additional BARDA Funding | GAITHERSBURG, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage... | citybizlis... |
| 12.03.2019 | Altimmune Closes $14M Registered Direct Offering | GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stag... | citybizlis... |
| 12.03.2019 | Altimmune Closes $14M Registered Direct Offering | GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stag... | archive.ci... |
| 08.10.2018 | Altimmune Closes on $16.9M in Funding | Altimmune, Inc. (Nasdaq: ALT), a Gaithersburg, MD-based clinical-stage immunotherapeutics company, c... | finsmes.co... |
| 03.10.2018 | Altimmune Closes on $16.9 Million in Funding | GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage... | citybizlis... |
| 17.09.2018 | Here’s a look at Maryland’s publicly-traded biotech companie... | When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government i... | technical.... |
| 17.08.2017 | Altimmune Announces $14.7 Million Series B | GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage ... | citybizlis... |
| - | Altimmune to Announce Year End 2017 Financial Results on Mar... | GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage ... | healthcap.... |
| - | Altimmune to Announce Second Quarter 2018 Financial Results ... | GAITHERSBURG, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage ... | healthcap.... |
| - | Altimmune Announces Pricing of $12 Million Underwritten Publ... | GAITHERSBURG, Md., Sept. 28, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage... | healthcap.... |
| - | Altimmune Announces Positive Results from NasoVAX Extension ... | Seroprotective HAI antibody response persisted more than one year after vaccination
Company seeking... | healthcap.... |
| - | Altimmune Announces Presentation of HepTcell Phase 1 Results... | GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage ... | healthcap.... |
| - | Altimmune Announces $4.9 million Registered Direct Offering ... | GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage... | healthcap.... |
| - | Altimmune Awarded $2.5 Million in Additional BARDA Funding t... | New funding will allow examination of mucosal immune response and additional vaccine characterizatio... | healthcap.... |
| - | Altimmune Receives $7.3 Million Contract Modification from B... | GAITHERSBURG, Md., March 28, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherape... | healthcap.... |
| - | Altimmune to Present at the 28th Annual Piper Jaffray Health... | GAITHERSBURG, Md., Nov. 18, 2016 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherapeu... | healthcap.... |
| - | Altimmune to Announce Second Quarter 2019 Financial Results ... | GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc.(Nasdaq: ALT), a clinical stage b... | healthcap.... |
| - | Altimmune Announces $14.7 Million Series B Preferred Stock O... | GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage i... | healthcap.... |
| - | Altimmune Announces Important Additions to its Patent Portfo... | GAITHERSBURG, Md., June 05, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc.(Nasdaq: ALT), a clinical-stage b... | healthcap.... |
| - | Altimmune Announces Acceptance of HepTcell Abstract for Pres... | GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) — Altimmune, Inc., a clinical stage immunotherapeu... | healthcap.... |
| - | Altimmune to Present at the BIO CEO & Investor Conferenc... | GAITHERSBURG, Md., Feb. 6, 2017 /PRNewswire/ — Altimmune, Inc., a clinical stage immunotherapeutics ... | healthcap.... |
| - | PharmAthene and Altimmune Announce Merger to Create Immunoth... | FOR IMMEDIATE RELEASE
Contact for Altimmune, Inc.
Bill Enright Investor Relations
President and C... | healthcap.... |
| - | Altimmune Announces Clinical Program Updates and Plans for P... | GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage ... | healthcap.... |
| - | Altimmune Announces First Quarter 2018 Financial Results and... | Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET
GAITHERSBURG, Md., May 15, ... | healthcap.... |
| - | Altimmune Expands Clinical Development Team | Appoints Sybil Tasker as Senior Vice President, Clinical Research and Development
Names Efe Egharev... | healthcap.... |
| - | Altimmune Announces $25 million Registered Direct Offering | GAITHERSBURG, Md., Oct. 08, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage ... | healthcap.... |
| - | Altimmune Restructures Financing Agreement | GAITHERSBURG, Md., June 22, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage i... | healthcap.... |
| - | Altimmune Announces Presentation at Biotech Showcase 2016 | Gaithersburg, Maryland – DEC. 21, 2015 – Altimmune, Inc., a clinical stage immunotherapeutic company... | healthcap.... |
| - | Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Of... | GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage... | healthcap.... |
| - | Altimmune Announces Financial Results for the Year Ended Dec... | Conference call and webcast scheduled for Tuesday, April 2, at 8:30 am Eastern Time
GAITHERSBURG, M... | healthcap.... |
| - | Altimmune To Present NasoVAX Phase 2 Data at the World Vacci... | Dr. Sybil Tasker to present on April 16 at 12:55pm Eastern Time
GAITHERSBURG, Md., April 11, 2019 (... | healthcap.... |
| - | Altimmune Completes Merger with PharmAthene Creating Immunot... | GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT) announced today the ... | healthcap.... |
| - | Altimmune Closes on $16.9 Million in Funding | $12 million underwritten public offering closed October 2
$4.9 million registered direct offering c... | healthcap.... |
| - | Altimmune Announces Second Quarter 2019 Financial Results an... | Conference Call & Webcast Scheduled for Wednesday, August 14, at 8:30am Eastern Time
GAITHERSBU... | healthcap.... |
| - | Altimmune Announces Positive Data From Its Phase 2a Study of... | NasoVAX intranasal influenza vaccine demonstrated strong cellular immune response and 100% seroprote... | healthcap.... |
